# A Smart Semiconductor based Integrated Continuous Diabetes Monitoring Platform

> **NIH NIH R43** · INTEGRATED MEDICAL SENSORS · 2023 · $100,000

## Abstract

PROJECT SUMMARY
The long-term goal of this project is to develop a scalable, user-friendly, continuous diabetes monitoring
(CDM) system to minimize the risk of diabetic ketoacidosis (DKA) for millions of diabetes patients,
especially those with type I diabetes by adding continuous ketone monitoring (CKM) to the IMS
continuous glucose monitor (CGM). IMS has developed the world's smallest wireless electrochemical
CGM using a novel semiconductor (CMOS) platform. This design offers some unique advantages due
to its smart sensor (compared to passive sensors in competitor designs) including extreme
miniaturization (system is smaller than half a sesame seed), on-chip integration of multiple sensors,
improvement in signal-to-noise ratio (thus improving hypoglycemia accuracy), decrease in sensor
capacitance and membrane thickness (thus improving response speed), and on-chip temperature
calibration. This system can enable automatic closed-loop glucose control without meal announcements
and carbohydrate counting and without the fear of missed hypoglycemic events; greatly simplifying
patient experience and improving safety.
We have demonstrated the function of our CGM platform in the lab, in animals, and recently in humans.
The addition of CKM can significantly improve the value of the system to detect impending DKA that
goes unnoticed with the current CGM systems, causing significant harm to the at-risk patients.
Therefore, our objective in the original proposal was to develop a multi-analyte sensing platform that
can sense both glucose and ketone in the interstitial fluid (ISF) using a single device. The sensing
platform would be tested in the lab.
This research is significant as it will enable the first CDM system with a small, pain-free needle-
insertion (26-gauge needle) that can work for a long time (>30 days). Once proven, this system can be
extended to include other important analytes (e.g., insulin, glucagon) without increasing its size or
complexity, owing to on-chip integration of multiple sensors on a single microscale device.
During our work, we discovered an unforeseen issue with the ketones sensing chemistry that prevents
long-term stability. We have discovered a potential solution to that by using a conjugated enzyme.
We need additional support via this supplement to enable us to test this solution.
The team includes original inventors of the core technology from California Institute of Technology (Dr.
Nazari, Dr. Rahman, Mr. Sencan), seasoned and respected researcher in Glucose sensor technology
(Bill Van Antwerp, former CSO of Medtronic MiniMed), surgery and biomaterials expert (Dr. Jonathan
Lakey of UC Irvine), regulatory and IP expert (John Heithaus, JD), commercialization expert (Mr. Peter
Rule; former President of MiniMed, Chairman of Therasense, and OptiScan), and clinical expert (Dr.
Alan Marcus, MD; former Chief Medical Officer of Medtronic Diabetes). The project is supported by
patient advocacy groups like JDRF and practicing endocr...

## Key facts

- **NIH application ID:** 10900360
- **Project number:** 3R43DK135084-01S1
- **Recipient organization:** INTEGRATED MEDICAL SENSORS
- **Principal Investigator:** Muhammad Mujeeb-U-Rahman
- **Activity code:** R43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $100,000
- **Award type:** 3
- **Project period:** 2023-04-10 → 2024-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10900360

## Citation

> US National Institutes of Health, RePORTER application 10900360, A Smart Semiconductor based Integrated Continuous Diabetes Monitoring Platform (3R43DK135084-01S1). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10900360. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*